Page 7 - While Moderna News Today : Breaking News, Live Updates & Top Stories | Vimarsana

By Parsa Erfani, Lawrence O. Gostin, and Vanessa Kerry May 19, 2021Reprints CRISTINA QUICLER/AFP via Getty Images The Biden administration’s announcement to support an intellectual property (IP) waiver for Covid-19 vaccines was a monumental step toward improving the access to them in low- and middle-income countries. But without further action, it will be little more than a symbol. The waiver allows companies to produce Covid-19 vaccines without fear of being sued by the entity that holds the IP for the technology. It had been backed by more than 100 countries and by 110 members of the U....

  Covid-19 Vaccine stocks – which includes U.S.-listed pharma and biotech companies. The theme is up by about 640% year-to-date versus about 13% for the S&P 500. [Updated 11/11/2020] Why Pfizer’s Vaccine Data Is Good News For Moderna While Pfizer‘s (NYSE: PFE) surprisingly strong initial Covid-19 vaccine efficacy readout likely marks the beginning of the end of the Covid-19 pandemic, it probably doesn’t mean too much for Pfizer stock, given the limited potential profits and challenges with distribution. In fact, we think that the strong data from the vaccine – which is developed...

Author Bio Taylor Carmichael is a former attorney and filmmaker. He's the author of a line of murder mysteries, including Whodidit in the Supreme Court? and Whodidit With a Senator? The majority of what he knows about stocks he learned right here at the Motley Fool. While Moderna (NASDAQ:MRNA) is famous for its COVID-19 vaccine, the biotech actually has a vast development pipeline for many other mRNA vaccines. This year, all the revenues are going to come from vaccinating people to stop COVID, but over the next decade, the company might have revenues from a variety of...

The company said it expects to reduce the number of days taken to produce a batch of COVID-19 vaccines from 110 to around 60.

Moderna's CEO Stéphane Bancel tells Axios the company's coronavirus vaccine made it to market in near-record time thanks in part to a unique digital foundation.The big picture: Moderna is far smaller than many of its pharma competitors, but it made one of the first authorized COVID-19 vaccines. But the company still needs to adapt to a mutating virus — and come up with its next blockbuster product.Support safe, smart, sane journalism. Sign up for Axios Newsletters here.What they're saying: While Moderna's SARS-CoV-2 vaccine is already beginning to make a dent in...